Anti-Inhibitor

Last Updated: 02/24/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 388 publications

In brief: Andexanet alfa (Andexxa) withdrawn.

In brief: Andexanet alfa (Andexxa) withdrawn.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Comparison of outcomes in autoimmune acquired factor XIII deficiency with and without underlying diseases: a systematic review.

Comparison of outcomes in autoimmune acquired factor XIII deficiency with and without underlying diseases: a systematic review.

Journal: Journal of thrombosis and thrombolysis

Published: June 29, 2025

Intraoperative Hemostatic Agents in Thoracic Aortic Surgery-A Scoping Review.

Intraoperative Hemostatic Agents in Thoracic Aortic Surgery-A Scoping Review.

Journal: Journal of clinical medicine

Published: May 07, 2025

Bleeding Complications, Transfusion, and Acute Care Costs After Major Arthroplasty in Patients With Hereditary Bleeding Disorders: A National Healthcare Database Analysis.

Bleeding Complications, Transfusion, and Acute Care Costs After Major Arthroplasty in Patients With Hereditary Bleeding Disorders: A National Healthcare Database Analysis.

Journal: Anesthesia and analgesia

Published: April 04, 2025

Spontaneous hemorrhage arising from a proximal descending branch of the suprascapular artery.

Spontaneous hemorrhage arising from a proximal descending branch of the suprascapular artery.

Journal: The American journal of emergency medicine

Published: February 17, 2025

Factor Eight Inhibitor Bypass Activity Use in Cardiac Surgery: A Propensity-matched Analysis of Safety Outcomes.

Factor Eight Inhibitor Bypass Activity Use in Cardiac Surgery: A Propensity-matched Analysis of Safety Outcomes.

Journal: Anesthesiology

Published: August 26, 2024

Prethrombin-1 as a Drug Substance Promoting Hemostasis with Reduced Risk of Thrombosis.

Prethrombin-1 as a Drug Substance Promoting Hemostasis with Reduced Risk of Thrombosis.

Journal: Thrombosis and haemostasis

Published: June 12, 2024

FEIBA: Too Potent a Potion or Just Right for Post-CPB Bleeding?

FEIBA: Too Potent a Potion or Just Right for Post-CPB Bleeding?

Journal: Journal of cardiothoracic and vascular anesthesia

Published: June 07, 2024

4-Factor prothrombin complex concentrates and factor VIII inhibitor bypass activity use in cardiac surgery.

4-Factor prothrombin complex concentrates and factor VIII inhibitor bypass activity use in cardiac surgery.

Journal: Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis

Published: May 06, 2024

Factor Eight Inhibitor Bypassing Activity as First-line Therapy for Coagulopathy in Cardiac Surgery.

Factor Eight Inhibitor Bypassing Activity as First-line Therapy for Coagulopathy in Cardiac Surgery.

Journal: Journal of cardiothoracic and vascular anesthesia

Published: March 21, 2024

Asymptomatic COVID-19-Associated Acquired Hemophilia A and Disseminated Intravascular Coagulation From a Bypassing Agent.

Asymptomatic COVID-19-Associated Acquired Hemophilia A and Disseminated Intravascular Coagulation From a Bypassing Agent.

Journal: Journal of medical cases

Published: March 07, 2024

Reader Comment: Continuing the Quest for Hemostasis: Can Factor Eight Inhibitor Bypassing Activity (FEIBA) Bypass Post-Pump Coagulopathy?

Reader Comment: Continuing the Quest for Hemostasis: Can Factor Eight Inhibitor Bypassing Activity (FEIBA) Bypass Post-Pump Coagulopathy?

Journal: World journal for pediatric & congenital heart surgery

Published: November 09, 2023

Showing 1-12 of 388

Last Updated: 02/24/2026